Molecule
Suzetrigine is a sodium channel blocker indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. It is available as tablets for oral use. MedsAcross supplies Suzetrigine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
JOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. JOURNAVX is a sodium channel blocker indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults.
Source: US FDA prescribing information
Suzetrigine is a selective blocker of the Na V 1.8 voltage-gated sodium channel, compared to other known voltage-gated sodium channels (Na V 1.1 through 1.9). Na V 1.8 is expressed in peripheral sensory neurons including dorsal root ganglion neurons, where its role is to transmit pain signals (action potentials). By selectively inhibiting Na V 1.8 channels, suzetrigine inhibits transmission of pain signals to the spinal cord and brain. M6-SUZ, a major active metabolite, is a less potent inhibitor of Na V 1.8 than suzetrigine by 3.7-fold.
Source: US FDA prescribing information
Swallow JOURNAVX tablets whole and do not chew or crush. Recommended starting JOURNAVX oral dose is 100 mg. Take the starting dose on an empty stomach at least 1 hour before or 2 hours after food. Clear liquids may be consumed during this time (e.g., water, apple juice, vegetable broth, tea, black coffee). Starting 12 hours after the starting dose, take 50 mg of JOURNAVX orally every 12 hours. Take these doses with or without food. Use JOURNAVX for the shortest duration, consistent with individual patient treatment goals. Use of JOURNAVX for the treatment of acute pain has not been studied beyond 14 days. See the full prescribing information for the recommended dosage in patients with hepatic impairment, for JOURNAVX dosage modifications with concomitant use of CYP3A inhibitors, and recommendations regarding missed dose(s).
Source: US FDA prescribing information
Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated. Concomitant use with strong CYP3A inhibitors is contraindicated.
Source: US FDA prescribing information
Moderate and Severe Hepatic Impairment: Avoid use in patients with severe hepatic impairment (Child-Pugh Class C). Use in patients with moderate hepatic impairment may increase the risk of adverse reactions. The recommended dosage is lower in patients with moderate hepatic impairment (Child-Pugh Class B) than those with normal hepatic function.
Source: US FDA prescribing information
The most common adverse reactions (greater incidence in JOURNAVX-treated patients compared to placebo-treated patients) were pruritus, muscle spasms, increased creatine phosphokinase, and rash.
Source: US FDA prescribing information
Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX.
Source: US FDA prescribing information
Store at 68°F to 77°F (20°C to 25°C), excursions permitted to 59°F to 86°F (15°C to 30°C).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Suzetrigine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Journavx 50 mg tabletOral | Vertex Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 30 January 2025 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Suzetrigine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Suzetrigine, including Journavx.
Yes. The US FDA first approved Suzetrigine on 30 January 2025, according to Drugs@FDA.
No listed presentation of Suzetrigine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.